Canadian COVID-19 Emergency Department Registry

Overview

Coronavirus Disease 2019 (COVID -19) is the largest public health crisis in over a century. There is an urgent need for high-quality population-level data to understand modifiable risks for disease severity, transmissibility, and to develop evidence-based prevention (i.e. vaccination), treatment and resource allocation strategies. The Canadian COVID-19 Emergency Department Rapid Response Network (CCEDRRN) created a population-based registry of suspected and confirmed consecutive cases of COVID-19. The purpose of this registry is to derive and validate clinical decision rules, evaluate diagnostic tests and vaccine effectiveness, and complete cohort, case-control and observational studies to inform the pandemic response.

Full Title of Study: “Canadian COVID-19 Emergency Department Rapid Response Network (CCEDRRN) – Population-based Registry of Suspected and Confirmed COVID-19 Cases”

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Other
  • Study Primary Completion Date: December 31, 2022

Detailed Description

This national multi-centre registry is designed to enroll population-based consecutive eligible patients presenting with suspected or confirmed COVID-19 to 50 emergency departments in eight Canadian provinces from March 1 2020 and data collection is ongoing for the duration of the pandemic. Data will be abstracted from the medical chart and entered into a central, web-based REDCap database. The investigators adopted the ISARIC variables into the database where there was a match. The investigators will develop standardized operating procedures for screening of potentially eligible patients, data entry and follow-up. Current data dictionaries are kept on the registry's website (https://canadiancovid19registry.org/). At 30 days, the investigators will contact patients by telephone to obtain verbal consent for follow-up. The investigators will measure the Veterans Rand 12-item Health Survey (VR12), calculate the WHO Ordinal Outcome Scale and ask contextual questions in consenting patients. The VR12 will be measured at 60 days, and 6 and 12 months. The contextual questions were developed with input from patients with lived experience with COVID-19 infection and addressed cultural, racial, gender, socioeconomic and self-isolation issues. The Health Data Research Network facilitated the development of a unique data flow of personal health identifiers and study identification numbers from each province for all participating institutes. This will allow linkage of registry data with national administrative data repositories.

Arms, Groups and Cohorts

  • Registry participants
    • Patients presenting to participating emergency departments with suspected and or confirmed COVID-19.

Clinical Trial Outcome Measures

Primary Measures

  • Confirmed COVID-19 diagnosis
    • Time Frame: 14 days
    • Biological specimen is tested positive for SARS-CoV-2 using reverse transcription polymerase chain reaction (RT PCR). The specimen had to be drawn within two weeks of the emergency department visit if the patient presented with a COVID-19-related complication. If the initial test was negative, the patient had to have a positive specimen within 14 days of the index visit.

Secondary Measures

  • Hospital admission
    • Time Frame: 30 days
    • Any hospital admission within 30 days of index emergency department visit captured in medical chart.
  • Mechanical ventilation
    • Time Frame: 30 days
    • Any mechanical ventilation during any hospital visit within 30 days of index emergency department visit captured in medical chart.
  • Emergency department revisits
    • Time Frame: 30 days
    • Any emergency department revisits within 30 days of index emergency department visit captured in medical chart.
  • Hospital re-admissions
    • Time Frame: 30 days
    • Any hospital re-admissions within 30 days of index emergency department visit date captured in medical chart.
  • 30 day mortality
    • Time Frame: 30 days
    • Any death captured within 30 days of index emergency department visit captured by medical charts.
  • Clinical recovery
    • Time Frame: 30 days
    • Captured through telephone follow-up using the World Health Organization Ordinal Outcome Scale at 30 days after index emergency department visit. The scale is scored from 1 to 8 (‘1’= no limitations to activities, ‘8’=death) to measure clinical improvement at 30 days.
  • Patient quality of life
    • Time Frame: 12 months
    • Captured through telephone follow-up using the Veterans Rand 12-item Health Survey at 30 days, 60 days, and 6 and 12 months after index emergency department visit.

Participating in This Clinical Trial

The investigators defined two periods for enrollment based on the availability of COVID-19 testing. Research assistants used medical microbiology testing and discharge diagnoses to screen for potentially eligible patients. In Period 1, COVID-19 testing in each province was restricted to specific patient populations (e.g., healthcare workers, admitted patients). Inclusion Criteria:

  • Meeting the WHO suspect COVID-19 criteria: Fever (self-reported or subjective fever) and at least one symptom/sign of respiratory illness (e.g., flu-like illness, cough, shortness of breath) – Presenting to the emergency department and tested for COVID-19 in the emergency department No exclusion criteria in Period 1 Period 2 started on the date which each province expanded testing criteria allowing clinicians to test patients based on clinical suspicion or policy. Inclusion Criteria:

  • Presenting to the emergency department within 14 days of a positive COVID-19 (by self-report or in medical chart) and presents with clinical symptoms consistent with COVID-19 – Tested for COVID-19 in the emergency department, or within 24 hours after emergency department arrival. Exclusion Criteria – Patients tested for COVID-19 in the context of an elective admission (e.g., planned hip revision) – Patients tested for COVID-19 and seen in the emergency department directly by another service (e.g., trauma team activation)

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of British Columbia
  • Collaborator
    • Genome British Columbia
  • Provider of Information About this Clinical Study
    • Principal Investigator: Corinne Hohl, Associate Professor – University of British Columbia
  • Overall Official(s)
    • Corinne M Hohl, MD, MSc, Principal Investigator, University of British Columbia
  • Overall Contact(s)
    • Corinne M Hohl, MD, MSc, 604-875-4111, corinne.hohl@ubc.ca

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.